Exenatide
Dapalost
AstraZeneca · Phase 2 · Completed · Enrollment 50
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Dapagliflozin and exenatide | Obesity or overweight | n/r | 24 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 24 | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Exenatide
AstraZeneca · Phase 2 · Completed · Enrollment 50
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Dapagliflozin and exenatide | Obesity or overweight | n/r | 24 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 24 | n/r | n/r |